Biodesix, Inc.
BDSX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $71 | $49 | $38 | $55 |
| % Growth | 45.3% | 28.5% | -29.9% | – |
| Cost of Goods Sold | $16 | $13 | $14 | $31 |
| Gross Profit | $56 | $36 | $24 | $24 |
| % Margin | 78.2% | 73.5% | 63% | 44% |
| R&D Expenses | $10 | $10 | $13 | $13 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $80 | $67 | $61 | $51 |
| Sales & Mktg Exp. | $0 | $0 | $61 | $51 |
| Other Operating Expenses | $0 | $0 | $0 | $2 |
| Operating Expenses | $90 | $77 | $75 | $65 |
| Operating Income | -$34 | -$41 | -$51 | -$41 |
| % Margin | -48.4% | -84.2% | -132.4% | -75.1% |
| Other Income/Exp. Net | -$8 | -$11 | -$15 | -$2 |
| Pre-Tax Income | -$43 | -$52 | -$65 | -$43 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$43 | -$52 | -$65 | -$43 |
| % Margin | -60.2% | -106.2% | -171.3% | -79.2% |
| EPS | -6.6 | -12.8 | -31 | -31.6 |
| % Growth | 48.4% | 58.7% | 1.9% | – |
| EPS Diluted | -6.6 | -12.8 | -31 | -31.6 |
| Weighted Avg Shares Out | 6 | 4 | 2 | 1 |
| Weighted Avg Shares Out Dil | 6 | 4 | 2 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $8 | $10 | $8 | $5 |
| Depreciation & Amortization | $5 | $6 | $6 | $3 |
| EBITDA | -$29 | -$37 | -$52 | -$35 |
| % Margin | -41% | -75.6% | -134.9% | -65.1% |